Article in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
3.6field-weighted citation impact, top 8% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 9 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors at 5 institutions in 3 countries.
Salah Abdalrazak AlshehadeDiscipline of Pharmacology, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Gelugor 11800, Penang, Malaysia.ORCID 0000-0001-8732-1883
Raghdaa Hamdan Al ZarzourDiscipline of Pharmacology, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Gelugor 11800, Penang, Malaysia.
Michael MathaiCollege of Health and Biomedicine, Victoria University, Melbourne, VIC 3011, Australia.
Nelli GiribabuDepartment of Physiology, Faculty of Medicine, Universiti Malaya, Kuala Lumpur 50603, Malaysia.
Atefehalsadat SeyedanDepartment of Pharmacology, Faculty of Medicine, Universiti Malaya, Kuala Lumpur 50603, Malaysia.
Gurjeet KaurInstitute for Research in Molecular Medicine, Universiti Sains Malaysia, Gelugor 11800, Penang, Malaysia.ORCID 0000-0002-6232-5703
Amin Malik Shah Abdul MajidEman Research Ltd., Level 3/81 Flushcombe Rd, Blacktown, NSW 2148, Australia.
Vikneswaran MurugaiyahDiscipline of Pharmacology, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Gelugor 11800, Penang, Malaysia.ORCID 0000-0003-1768-7577
Hassan AlmoustafaDepartment of Pharmacology, Faculty of Medicine, Universiti Malaya, Kuala Lumpur 50603, Malaysia.ORCID 0000-0002-2549-1761
Mohammed Abdullah AlshawshDepartment of Pharmacology, Faculty of Medicine, Universiti Malaya, Kuala Lumpur 50603, Malaysia.ORCID 0000-0001-8342-5183
Universiti Sains Malaysia · MYUniversity of Malaya · MYAustralian National University · AUSultan Abdul Halim Hospital · MYVictoria University · AU
Funding
Universiti Sains Malaysia 304/PFARMASI/6315201Universiti Sains Malaysia FRGS/1/2021/SKK0/USM/02/27University of Malaya ST070-2021
6 · The paper itself
Abstract
Non-alcoholic fatty liver disease (NAFLD) is the most prevalent form of liver disease.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.